Unveiling 14 Analyst Insights On Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 14 analysts have shared their insights on Axsome Therapeutics (NASDAQ:AXSM), with a majority expressing bullish sentiments. The average 12-month price target is $132.14, with a high of $190.00 and a low of $95.00. Axsome Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth but faces challenges in profitability and financial returns.
August 22, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics has received mostly bullish ratings from analysts, with an average price target of $132.14. The company has shown strong revenue growth but faces challenges in profitability and financial returns.
The majority of analysts have a bullish outlook on Axsome Therapeutics, indicating positive sentiment which could lead to a short-term price increase. The company's strong revenue growth supports this sentiment, although challenges in profitability may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100